Daniel J. George, MD, discusses the expanding role of cabozantinib in renal cell carcinoma.
Daniel J. George, MD, professor of medicine and surgery, and member, Duke Cancer Institute, discusses the expanding role of cabozantinib (Cabometyx) in renal cell carcinoma (RCC).
Cabozantinib is a VEGF inhibitor that was specifically designed to target MET and AXL, in addition to VEGF, says George.
Clinical validation of the efficacy of cabozantinib in RCC has been observed in multiple clinical trials over the past decade, George explains. Moreover, as cabozantinib selectively inhibits MET and AXL, the agent has demonstrated theorectical advantage compared with other VEGF inhibitors.
The agent has FDA indications in the frontline and relapsed/refractory settings for patients with RCC, George says.
Additionally, combining cabozantinib with other agents, such as nivolumab (Opdivo), may enhance the utility of the agent in the RCC paradigm, concludes George.